Wnt/β-catenin pathway as a potential target for Parkinson's disease: a cohort study of romosozumab using routinely collected health data in Japan
IntroductionRomosozumab is a monoclonal antibody approved for osteoporosis which targets sclerostin, an endogenous inhibitor of Wnt/β-catenin pathway. Given the essential roles of the Wnt/β-catenin pathway in various tissues, we hypothesized romosozumab treatment may influence other conditions.Metho...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Llibre |
| Publicat: |
Frontiers Media S.A.,
2024-07-01T00:00:00Z.
|
| Matèries: | |
| Accés en línia: | Connect to this object online. |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signatura: |
A1234.567 |
|---|---|
| Còpia 1 | Disponible |